Olaizola Miguel
Mera Pharmaceuticals Inc., 73-4460 Queen Kaahumanu Hwy., Suite 110, Kailua-Kona, HI 96740, USA.
Biomol Eng. 2003 Jul;20(4-6):459-66. doi: 10.1016/s1389-0344(03)00076-5.
While humans have taken limited advantage of natural populations of microalgae for centuries (Nostoc in Asia and Spirulina in Africa and North America for sustenance), it is only recently that we have come to realize the potential of microalgal biotechnology. Microalgal biotechnology has the potential to produce a vast array of products including foodstuffs, industrial chemicals, compounds with therapeutic applications and bioremediation solutions from a virtually untapped source. From an industrial (i.e. commercial) perspective, the goal of microalgal biotechnology is to make money by developing marketable products. For such a business to succeed the following steps must be taken: identify a desirable metabolite and a microalga that produces and accumulates the desired metabolite, establish a large-scale production process for the desired metabolite, and market the desired metabolite. So far, the commercial achievements of microalgal biotechnology have been modest. Microalgae that produce dozens of desirable metabolites have been identified. Aided by high throughput screening technology even more leads will become available. However, the successes in large-scale production and product marketing have been few. We will discuss those achievements and difficulties from the industrial point of view by considering examples from industry, specially our own experience at Mera Pharmaceuticals.
几个世纪以来,人类对微藻自然种群的利用一直有限(亚洲的发菜以及非洲和北美的螺旋藻用于维持生计),直到最近我们才开始认识到微藻生物技术的潜力。微藻生物技术有潜力从几乎未开发的资源中生产出大量产品,包括食品、工业化学品、具有治疗应用的化合物以及生物修复解决方案。从工业(即商业)角度来看,微藻生物技术的目标是通过开发可销售的产品来盈利。要使这样的业务取得成功,必须采取以下步骤:确定一种理想的代谢产物以及能够产生并积累该理想代谢产物的微藻,建立该理想代谢产物的大规模生产工艺,并将该理想代谢产物推向市场。到目前为止,微藻生物技术的商业成就并不显著。已经鉴定出能够产生数十种理想代谢产物的微藻。借助高通量筛选技术,将会有更多线索出现。然而,大规模生产和产品营销方面的成功案例却很少。我们将通过考虑来自工业界的例子,特别是我们在美拉制药公司的自身经验,从工业角度来讨论这些成就和困难。